Neuromedin U (NMU) is a neuropeptide originally isolated from porcine spinal cord that plays roles in appetite suppression, energy expenditure, stress response, and smooth muscle contraction. It acts through two G-protein-coupled receptors (NMUR1 peripherally and NMUR2 centrally). Preclinical studies show potent anorexigenic effects, with central NMU administration reducing food intake more effectively than many other appetite-suppressing peptides. It is being explored as a potential obesity therapeutic target.
Category: Metabolic / Appetite. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical. No human clinical trials for NMU itself. Long-acting NMU analogs are in early development.
NMU binds to NMUR2 in the hypothalamic paraventricular nucleus (PVN) and arcuate nucleus to suppress appetite and increase sympathetic tone, raising energy expenditure. Peripheral NMUR1 activation in the gut modulates motility and insulin secretion. NMU also activates the HPA axis (increasing CRH…
Safety considerations: No human safety data available; HPA axis activation (increased cortisol/corticosterone) is a consistent finding in animal studies; Stress response activation may limit tolerability in humans.
Reviewed by the PeptideAtlas Editorial Team.
| Molecular weight | ~2846 g/mol (NMU-25) |
|---|---|
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | Not FDA-approved. Research compound only. |
Not currently. While NMU is one of the most potent appetite-suppressing peptides known, its very short half-life and HPA axis activation make the native peptide impractical as a therapeutic. Long-acting NMU analogs are in early preclinical development.
NMU acts through completely different receptors and pathways (NMUR1/2 vs GLP-1R). Its appetite-suppressing effects in animals are potent, but it lacks the clinical development and safety data that GLP-1 agonists have. Combination approaches are being explored.
Yes. NMU is a potent activator of the hypothalamic-pituitary-adrenal (HPA) axis. Central NMU administration increases CRH, ACTH, and corticosterone in rodents. This stress activation is a significant barrier to therapeutic development.